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ABSTRACT: Age-related macular degeneration (AMD)
is the most common cause of incurable visual impair-
ment in high-income countries. Previous studies report
inconsistent associations between AMD and apolipopro-
tein E (APOE), a lipid transport protein involved in
low-density cholesterol modulation. Potential interaction
between APOE and sex, and smoking status has been re-
ported. We present a pooled analysis (n = 21,160) demon-
strating associations between late AMD andAPOε4 (odds
ratio [OR] = 0.72 per haplotype; confidence interval [CI]:
0.65–0.74; P = 4.41×10−11) and APOε2 (OR = 1.83 for
homozygote carriers; CI: 1.04–3.23; P = 0.04), follow-
ing adjustment for age group and sex within each study
and smoking status. No evidence of interaction between
APOE and sex or smoking was found. Ever smokers
had significant increased risk relative to never smokers
for both neovascular (OR = 1.54; CI: 1.38–1.72; P =
2.8×10−15) and atrophic (OR = 1.38; CI: 1.18–1.61;
P = 3.37×10−5) AMD but not early AMD (OR = 0.94;
CI: 0.86–1.03; P = 0.16), implicating smoking as a ma-
jor contributing factor to disease progression from early
signs to the visually disabling late forms. Extended hap-
lotype analysis incorporating rs405509 did not identify
additional risks beyond ε2 and ε4 haplotypes. Our ex-
panded analysis substantially improves our understanding
of the association between the APOE locus and AMD. It
further provides evidence supporting the role of choles-
terol modulation, and low-density cholesterol specifically,
in AMD disease etiology.
HumMutat 32:1407–1416, 2011. C© 2011Wiley Periodicals, Inc.
KEY WORDS: age-related macular degeneration; AMD;
apolipoprotein E; APOE; case-control association study
Introduction
Age-relatedmacular degeneration (AMD;MIM# 603075) is in its
late form, the leading cause of incurable visual impairment among
individuals of European descent over the age of 50 [Centers for Dis-
ease Control and Prevention, 2004], accounting for more than half
of all new cases of registered blindness [Evans andWormald, 1996].
The socioeconomic burden associated with AMD is increasing in
our aging societieswith almost 30%of those aged 75 years and above
showing early signs of disease [Klein et al., 1992; Vingerling et al.,
1995]. AMD is a common disorder of complex etiology with mul-
tiple genetic, environmental, and lifestyle factors contributing to
the phenotype, although the specifics of the etiology remain largely
unresolved [Swaroop et al., 2007]. AMD by definition affects the
macular region of the retina that is associated with detailed central
vision. AMD is commonly divided into early AMD (eAMD) and
late AMD, and the vision impairing late AMD is subdivided into
geographic atrophic (GA) and neovascular (NV) AMD or mixed
GA and NV together (GANV). eAMD is characterized by drusen
formation and pigmentary changes at the level of the retinal pig-
ment epithelium (RPE), and can progress through atrophy of the
pigment epithelium to the visually disabling late atrophic and/or
NV phenotypes.
Advances in our understanding of the genetic basis of the disease
have identified risk and protective variants in several genes associ-
ated with the complement pathway and chronic inflammation such
as factor H (CFH) [Edwards et al., 2005, Hageman et al., 2005;
Haines et al., 2005; Hughes et al., 2006; Klein et al., 2005], com-
ponent 2 (CC2)/factor B (CFB) region [Gold et al., 2006; McKay
et al., 2009], component 3 (C3) [Maller et al., 2007; McKay et al.,
2010; Park et al., 2009; Yates et al., 2007], and complement factor
I (CFI) [Fagerness et al., 2009]. Beyond the complement pathway,
chromosome 10q26 and specifically the age-related maculopathy
susceptibility 2 (ARMS2) locus has been implicated as a second
major genetic contributor to the AMD disease process [Dewan
et al., 2006; Jakobsdottir et al., 2005; Rivera et al., 2005; Yang et al.,
2006]. The high linkage disequilibrium that exists between ARMS2
and the serine protease HTRA1 makes it difficult to determine the
source of the genetic effect at this locus, although data have been
reported supporting mitochondrial involvement through interac-
tion with translocase of outer mitochondrial membrane proteins
and colocalization to the mitochondrial-rich ellipsoid region of the
photoreceptors [Fritsche et al., 2008; Kanda et al., 2007]. Mitochon-
drial dysfunction and oxidative stress have been implicated in AMD
disease etiology with reports of increased mitochondrial damage
in the neural retina and RPE with ageing. Reports of mitochon-
drial genomic variation and associated increased AMD risk [Canter
et al., 2008; San Giovanni et al., 2009] provide an excellent rationale
for the involvement of oxidative stress in the disease pathway. More
recently, TIMP3, a metalloproteinase involved in degradation of the
extracellular matrix, hepatic lipase C (LIPC), and cholesterylester
transfer protein (CETP), key genes involved in the metabolism of
triglycerides and high-density lipoproteins (HDL), were implicated
in AMD pathogenesis through genome-wide association studies
(GWAS) [Chen et al., 2010; Neale et al., 2010].
One of the first reported genetic associations with AMD was
the protective effect exerted by the ε4 haplotype of apolipoprotein E
(APOE;MIM#107741), a lipid transport protein that acts as a ligand
for the low-density lipoprotein (LDL) receptor, which is involved
in the maintenance and repair of neuronal cell membranes [Klaver
et al., 1998; Souied et al., 1998]. Association of APOE with AMD
pathogenesis is supportive of mechanisms such as immunoregu-
lation and cell signaling [Zarbin, 2004]. Variation at two single
nucleotide polymorphisms (SNPs) within the coding sequence of
the APOE gene, rs429358 and rs7412, results in different isoforms
reported to attenuate binding affinity to the LDL receptor. For ex-
ample, ε2 has a much reduced binding affinity leading to lower total
cholesterol levels with respect to ε3 and ε4, which reveal a higher
binding affinitywithhigher total cholesterol levels [Siest et al., 1995].
Three allelic variants derived from these SNPs commonly referred to
as ε2, ε3, and ε4 are differentiated on the basis of cysteine (Cys) and
arginine (Arg) residue interchanges at positions 112 (rs429358) and
158 (rs7412) in the amino acid sequence and give rise to 6 diplo-
types (ε3/ε3, ε3/ε4, ε2/ε3, ε4/ε4, ε2/ε4, and ε2/ε2, ranked from
most to least common among European populations [Corbo and
Scacchi, 1999]). The ε2 haplotype has a Cys residue at positions
112 and 158 in the receptor-binding region of APOE. The ε3 hap-
lotype has residues Cys-112 and Arg-158 and the ε4 haplotype has
Arg residues at both positions, with these amino acid substitutions
having a strong physiological consequence on protein function. ε3
is by far the most common haplotype in all human populations, but
considerable variation in the frequency distribution of all haplo-
types have been reported across different ethnic groups [Corbo and
Scacchi, 1999] and with human longevity [McKay et al., 2011].
Many independent replications of AMD and APOE have been
undertaken and while the protective effect associated with ε4 was
confirmed in some studies, the significance of the increased risk
associated with ε2 has not been consistent [Baird et al., 2004, 2006;
Bergeron-Sawitzke et al., 2009; Bojanowski et al., 2006; Conley
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Table 1. Summary Data on Subjects from Contributing Studies Showing Sample Size, Disease Status, Average Age and Sex
Composition, and Smoking Status
All subjects
Study Unaffected n Average age Affected n Average age eAMD n (%) GA n (%) NV n (%) GANV n (%) Male (%) Never smoker (%)
Belfast 436 74.8 479 77.4 29 s(0.06) 31 (0.06) 419 (0.88) 0 (0.00) 39 54
Regensburg 553 76.2 724 76.7 85 (0.12) 143 (0.20) 391 (0.54) 105 (0.15) 37 87
Portland 272 73.9 646 78.1 0 (0.00) 162 (0.25) 422 (0.65) 62 (0.10) 38 46
Rotterdam 3805 67.5 554 76.5 451 (0.81) 43 (0.08) 34 (0.06) 26 (0.05) 41 37
AREDS 199 77.1 879 79.9 240 (0.27) 162 (0.18) 306 (0.35) 171 (0.19) 42 47
Melbourne 106 71.5 202 74.7 36 (0.18) 37 (0.19) 98 (0.49) 28 (0.14) 38 46
Philadelphia 379 75.6 519 80.1 153 (0.29) 38 (0.07) 263 (0.51) 65 (0.13) 43 57
WHI-SEa 1283 73.7 422 74.5 374 (0.89) 13 (0.03) 31 (0.07) 4 (0.01) 0 55
Edinburgh 179 73.2 325 75.8 134 (0.41) 38 (0.12) 153 (0.47) 0 (0.00) 38 47
Southampton 458 70.7 468 78.4 183 (0.39) 58 (0.12) 102 (0.22) 125 (0.27) 42 39
Los Angeles 142 72.5 639 70.0 52 (0.08) 152 (0.24) 254 (0.40) 177 (0.28) 38 45
EUREYE 1935 72.3 2254 73.8 2114 (0.94) 42 (0.02) 98 (0.04) 0 (0.00) 45 53
Michigan 253 76.6 494 80.3 62 (0.12) 117 (0.24) 195 (0.40) 120 (0.24) 39 44
Cambridge 417 75.0 840 79.0 29 (0.03) 141 (0.17) 550 (0.66) 120 (0.14) 43 39
London 206 74.9 1099 77.3 201 (0.18) 193 (0.18) 619 (0.56) 86 (0.08) 36 37
Total 10623 71.5 10544 76.5 4143 (0.39) 1370 (0.13) 3935 (0.37) 1089 (0.10) 38 50
AREDS: age-related eye disease study; aWHI-SE: women’s health initiative-sight exam.
et al., 2005; Francis et al., 2009; Fritsche et al., 2009; Schmidt et al.,
2002, 2005; Thakkinstian et al., 2006; van Leeuwen et al., 2004;
Zareparsi et al., 2004]. Some studies have reported increased risk of
AMD associated with ε2 [Baird et al., 2004; Schmidt et al., 2002;
van Leeuwen et al., 2004; Zareparsi et al., 2004] while others have
suggested that effect modification by sex [Baird et al., 2004; Schmidt
et al., 2002] or smoking status may occur [Schmidt et al., 2005].
Previously, pooled data and meta-analyses in much smaller sample
sizes indicated a significant protective effect associated with ε4 and a
nonsignificant increased risk associated with ε2 [Bojanowski et al.,
2006; Thakkinstian et al., 2006]. In our investigation, we invited
contributing studies to pool individual sample data to assess APOE
genotype in AMDwith respect to accompanying clinical phenotype
data and to test for interaction with sex, age, and smoking status.
Materials and Methods
Study Population, Risk Factors, and Clinical Phenotypes
Initially 18 research groups likely to have APOE genetic data in
a well-phenotyped dataset were invited to participate. The analy-
sis originated from 15 of these studies in 40 centers based in 11
countries that had data on APOE in AMD patients and suitable
controls: nine European countries (United Kingdom, Germany, the
Netherlands, Norway, Estonia, Italy, France, Greece, and Spain), six
centers in theUnited States andone inAustralia [Augood et al., 2004;
Baird et al., 2006; Bergeron-Sawitzke et al., 2009; Conley et al., 2005;
Dandekar et al., 2006; Ennis et al., 2008; Francis et al., 2009; Fritsche
et al., 2009; Haan et al., 2006; Hadley et al., 2010; McKay et al., 2009;
Vingerling et al., 1995; Yates et al., 2007; Zareparsi et al., 2004]. Study
demographics are summarized (n = 21,160; Table 1). Three studies,
the Rotterdam study [Vingerling et al., 1995], the Women’s Health
Initiative (WHI) [Haan et al., 2006], and the European Eye Study
(EUREYE) study [Augood et al., 2004], provided data derived from
samples acquired through population-based surveys (n = 10,253).
The remainder of the data originated from case–control (associa-
tion) studies. Individual participant data for age at examination, sex,
smoking status (ever smoker or never smoker), AMD phenotype,
andAPOE haplotype (SNPs; rs429358, rs7412) were necessary from
participating studies to facilitate a pooled data analysis in order to be
eligible for this study. APOE genotypes were determined using sev-
eralmethods: TaqMan genotyping technology (Applied Biosystems,
Foster City, CA): Portland, AREDS, Philadelphia, Edinburgh,WHI,
Cambridge, London; APOE-specific polymerase chain reaction
followed by restriction digest: Michigan, Rotterdam, Melbourne,
Los Angeles, Cambridge; KASPar genotyping (KBioscience,
Hertfordshire, UK): EUREYE, Southampton; Sequenom (San
Diego,CA):Regensburg; BigDyeTerminatorDNACycle Sequencing
analysis (Applied Biosystems): Belfast. Where available, genotypes
were also requested for rs405509, a SNP located in the promoter
region of APOE (n = 7,568). Extended haplotype frequencies were
estimatedusingUNPHASED,wheredatawere available for rs405509
[Dudbridge, 2008].
Control subjects were classified on the basis of direct clinical
examination or by retinal imaging and were graded as having either
no signs of AMD in either eye, or had fewer than five hard drusen
of diameter ≤ 63μm and no focal pigmentary irregularities such
as hyperpigmentation or hypopigmentation (i.e., grades 0a and 0b
using the definitions of the Wisconsin Age-Related Maculopathy
GradingSystem;n=10,623).Caseswere classified according toAMD
diagnosis in the worst eye. Participants with drusen > 63μm and/or
focal pigmentary irregularities but had not progressed to late AMD,
were classified as eAMD (i.e., grades 1a–3; n = 4,143). Late AMD
was defined as those individuals with geographic atrophy (grade 4a)
and/or exudative AMD (grade 4b) in at least one eye. Samples
with late AMD were subcategorized to those with NV without GA
(n = 3,935), GA without NV (n = 1,370), and both NV and GA in
the same or fellow eye (GANV; n = 1,089). Cases of macular disease
due to other primary causes that mimic NV AMD, such as myopic
maculopathy, adult vitelliform, any retinal scarring, and idiopathic
macular telangiectasia, were excluded.
All participants provided prior written informed consent, and
the protocols were reviewed and approved by local institutional re-
view boards. Recruitment procedures and detailed AMD grading
methods for each study have been described previously [Augood
et al., 2004; Baird et al., 2006; Bergeron-Sawitzke et al., 2009; Con-
ley et al., 2005; Dandekar et al., 2006; Ennis et al., 2008; Francis
et al., 2009; Fritsche et al., 2009; Haan et al., 2006; Hadley et al.,
2010; McKay et al., 2009; Vingerling et al., 1995; Yates et al., 2007;
Zareparsi et al., 2004].
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Statistical Analysis
Analysis was restricted to samples derived from participants of
self-reportedEuropeandescent andwhohadbeen assessed forAMD
through retinal photography or clinical examination. Call rates for
all SNPs were verified and minor allele frequencies assessed; depar-
ture from Hardy–Weinberg Equilibrium (HWE) was determined
separately in cases and controls, using the χ2 goodness-of-fit test
(P < 0.01). Associations between haplotype and AMD and possi-
ble effect modification by smoking, age, and sex were assessed using
likelihood-ratioχ2 tests in the logistic regressionmodel. Sex and age
were considered to be potential confounding variables, particularly
in population surveys where cases of AMD were older and more
often female than those who were AMD free. To allow for this and
also for the different control group selection criteria employed in the
various case–control studies, sex and age (categorized in five year
groups) were included in all logistic regression models as were in-
teractions between sex and study and between age group and study.
Similar findings were obtained with age treated as a continuous
variable rather than categorized.
To assess the most appropriate genetic model two diplotype anal-
yses were explored separately with ε3ε3 assigned as the reference
group in each: (1) ε2ε2, ε2ε3, and ε3ε3; and (2) ε4ε4, ε3ε4, and
ε3ε3. The diplotype effects were estimated using the model-free
approach [Minelli et al., 2005], which does not assume that the
underlying genetic model is known in advance and makes use of
the information available on all diplotypes. Odds ratios (ORs), OR1
(comparing ε2ε2 with ε3ε3), OR2 (ε2ε3 vs. ε3ε3), OR3 (ε4ε4 vs.
ε3ε3), and OR4 (ε3ε4 vs. ε3ε3) were estimated, adjusting for study,
age group, sex, and smoking status, using methods previously de-
scribed [Minelli et al., 2005; Thakkinstian et al., 2006]. These ORs
were modeled on a logarithmic scale accounting for both between
andwithin study variation. The ratiosλ1 = logOR2/logOR1 andλ2 =
log OR4/log OR3 were estimated. These parameters capture infor-
mation about the genetic model, as follows; the model is recessive
if λ = 0, dominant if λ = 1, and additive if λ = 0.5. A homozygous
or heterosis model is appropriate for λ > 1 or λ < 0. Additionally,
logistic regression was used to fit various genetic models and the
Akaike Information Criteria was calculated to choose the most ap-
propriate genetic model. ORs with 95% confidence intervals (CIs)
were then estimated after first checking that there was no evidence
of heterogeneity in genetic effects between studies. This was done
using likelihood-ratio tests to assess the significance of interactions
in the logistic model.
Multinomial logistic regression was used to test if the contribu-
tion of APOE and smoking to AMD varied between the three late
AMD subphenotypes (GA, NV, and GANV) and between eAMD
and late AMD. In these analyses, the various disease subgroups were
compared with a common control group. The multinomial logistic
regression was fitted using the mlogit command in STATA (Stata-
Corp, College Station, TX) while the remainder of the analysis was
performed in SPSS (SPSS Inc, Chicago, IL).
Results
APOE Haplotype and Diplotype Frequencies
Of the 10,537 classified cases, 4,143 (39%) were categorized as
eAMD and 6,394 (61%) as late AMD (Table 1). Late AMD cases
were further categorized by subphenotype: GA: n = 1,370 (21%);
NV: n = 3,935 (62%); and GANV: n = 1,089 (17%).APOE haplotype
frequencies in controls varied between studies ranging from 6.7%
to 10.8% for ε2, 70.8% to 81.8% for ε3, and 9.5% to 20.8% for ε4
(Supp. Table S1). APOE haplotype frequencies also differed by phe-
notype with less variation in ε2 (7.9–10.2%) and ε3 (78.0–80.9%)
than in ε4 (9.1–14.1%) (Supp. Table S2). No evidence for departure
from HWE was detected in participating studies for any SNP, and
genotyping quality control metrics are provided (Supp. Table S3).
Assessment of Genetic Model
The most appropriate genetic models for the APOE diplotypes
were assessed from parameters λ1 and λ2 representing the ratio of
risks in specific diplotypes [Minelli et al., 2005]. The parameter λ2,
estimated as 0.49 (CI: 0.29–0.89), was strongly indicative of an ad-
ditive model for ε4 (λ2 = 0.5). The parameter λ1 was estimated at
0.14 (CI: 0.01–0.89) suggesting a recessive model for ε2 was likely
(λ1 = 0) although an additive model (λ1 = 0.5) could not be ex-
cluded (Table 2). This choice of model was further supported by the
Akaike Information Criteria that attained its minimum value for
the recessive model (12807.37) compared to the values obtained for
the general (12809.37), additive (12811.34), and dominant mod-
els (12811.84). This model is most in keeping with the diplotype
comparisons shown in Figure 1 (ε2ε3 and ε2ε4 vs. ε3ε3), which
clearly indicateminimal increase in risk associatedwith a single copy
of ε2.
Association of APOEwith Late AMD
Initial comparison of diplotype frequencies between late AMD
and controls used the ε3ε3 diplotype as a reference for calculating
ORs, CI, and P values. ORs were estimated after adjustment for
age group and sex within each study and for smoking status (ever
vs. never). The ε2ε2 diplotype showed a significantly increased risk
for late AMD after adjustment for age group and sex within each
study and for smoking status (OR = 1.83; CI: 1.04–3.23; P = 0.04),
with nonsignificant differences in risk associated with the two het-
erozygous ε2 diplotypes (ε2ε3: OR = 0.97; CI: 0.85–1.10; P = 0.62;
ε2ε4: OR = 0.88; CI: 0.64–1.20; P = 0.41) relative to the reference
ε3ε3 diplotype. Both the heterozygous ε3ε4 diplotype (OR = 0.71;
CI: 0.64–0.80; P = 5.54 × 10–9) and the homozygous ε4ε4 diplotype
(OR = 0.45; CI: 0.29–0.69; P = 2.97 × 10–4) showed significantly
decreased risks compared to the reference ε3ε3 diplotype for late
AMD (Fig. 1).
The estimate of the risk per ε4 haplotypewith late AMDwasOR=
0.72; CI: 0.65–0.79; P = 4.41 × 10–11. Addition of interaction terms
to the logistic model suggested no evidence of heterogeneity of the
ε4 haplotype risk between studies (χ2 = 15.0, df = 14, P = 0.38;
Fig. 2). The risk estimate for the ε2ε2 diplotype relative to the ε3ε3
diplotypewasOR=1.83;CI: 1.04–3.23;P=0.036,with little evidence
of heterogeneity between studies (χ2 = 19.8, df = 14, P = 0.14).
Analyses of APOE Diplotype and AMD Subphenotype
Tests for heterogeneity of the OR for ε4 between studies were not
significant for any of the four AMD subphenotypes (NV: χ2 = 12.0,
df = 14, P = 0.61; GA: χ2 = 9.90, df = 14, P = 0.77; GANV: χ2 = 15.2,
df = 14, P = 0.37; eAMD: χ2 = 19.4, df = 14, P = 0.15). These results
indicate that risk estimates per ε4 haplotype were homogeneous
across studies and so can be validly pooled. Corresponding tests for
the ε2ε2 diplotype were not considered robust because of the very
low frequency of this diplotype and consequently are not presented.
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Figure 1. Analysis of APOE diplotype and late AMD. Late AMD in-
cludes categories GA, NV, and GANV. ORs against the reference (ε3ε3),
95% CIs, and P values were adjusted for age group and gender within
each study and for smoking status (ever vs. never smoker).
Figure 2. ORs and CIs for late AMD calculated for one copy of ε4
by study (additive model with adjustment for age group and gender
within each study and for smoking status). Meta-analyses tests for
heterogeneity of ε4 effects between studies were not significant either
for late AMD (χ 2 = 15.0, df = 14, P = 0.38) or for any AMD subphenotype
(NV:χ 2 = 12.0, df = 14, P = 0.61; GA:χ 2 = 9.90, df = 14, P = 0.77; GANV:χ 2 =
15.2, df = 14, P = 0.37; eAMD: χ 2 = 19.4, df = 14, P = 0.15).
Assessment of ε2ε2 risk by AMD subphenotype (Table 2) resulted
in similar nonsignificant increases in risk after adjustment for age
group, sex, smoking status, and ε4 (NV: OR = 1.86; CI: 1.00–3.48;
GA: OR = 1.59; CI: 0.68–3.69; GANV: OR = 1.82; CI: 0.68–4.85;
eAMD: OR = 1.59; CI: 0.96–2.65). Multinomial logistic regression
analysis showed no significant difference in the ε2ε2 effect between
the three late AMD subphenotypes (χ2 = 0.35, df = 2, P = 0.84)
or between all late AMD combined and eAMD (χ2 = 0.01, df = 1,
P = 0.91) (Fig. 3A).
There was a significant decrease in risk associated with each
copy of ε4 (Table 2) in all AMD subphenotypes (NV: OR = 0.74;
CI: 0.66–0.83; GA: OR = 0.65; CI: 0.55–0.77; GANV: OR = 0.71; CI:
0.59–0.85; eAMD: OR = 0.84; CI: 0.77–0.92) after adjustment for
age group, sex, smoking status, and ε2. The multinomial logistic
model tests for differences in the ε4 effects between the three late
AMD subphenotypes (χ2 = 4.33, df = 2, P = 0.11) and between all
late AMDand eAMD (χ2 = 2.52, df = 1, P = 0.11) were not significant
(Fig. 3B).
Sex and APOE Haplotype
Due to variability in recruitment procedures, including the use
of some spouse controls in several of the case–control studies, sex
was treated primarily as a confounder rather than an independent
risk factor in the analysis. However, tests for differences between
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Figure 3. Odds ratio associated with (A) ε2 diplotype (recessive
model) and (B) ε4 haplotype and late AMD (GA, NV, and GANV samples
combined) were estimated after adjustment for age group and gender
within each study and smoking status. A: ε2 diplotype (recessive model):
OR = 1.83; CI: 1.04–3.23; P = 0.04 (Table 2). B: ε4 per haplotype (additive
model): OR = 0.72; CI: 0.65–0.79; P = 4.41 × 10−11 (Table 2). No significant
heterogeneity in associated risk was detected between each late AMD
subphenotype (ε2ε2: χ 2 = 0.35, df = 2, P = 0.84; ε4: χ 2 = 4.33, df = 2, P =
0.11) or between all late AMD and eAMD (ε2ε2: χ 2 = 0.01, df = 1, P =
0.91; ε4: χ 2 = 2.52, df = 1, P = 0.11).
sexes were estimated in the late AMD risk associated with APOE by
fitting interaction terms within the logistic regression model. These
indicated no effect modification by sex for either ε2 (χ2 = 0.56, df =
1, P = 0.46) or ε4 (χ2 = 0.47, df = 1, P = 0.49). Analysis of APOE
diplotype and late AMD inmales and females separately is presented
in Supp. Figure S1.
Smoking Status and AMD
Smoking status (ever smoker vs. never smoker) was associated
with a highly significant increased risk for late AMD after adjust-
ment for age group and sex (OR: 1.50;CI: 1.36–1.65:P= 7.92× 10–17;
Table 2). Tests for differences between ever smokers andnever smok-
ers in the late AMD risk associated with APOE were obtained by
fitting interaction terms. These indicated no effect modification by
smoking for either ε2 (χ2 = 0.46, df = 1, P = 0.50) or ε4 (χ2 = 2.27,
df = 1, P = 0.13).
Although smoking status was not significantly associated with
increased risk in eAMD (OR = 0.94; CI: 0.86–1.03; P = 0.16), it was
significantly associated with each of the late AMD subphenotypes
(NV:OR = 1.54; CI: 1.38–1.72; GA:OR = 1.38; CI: 1.18–1.61; GANV:
OR = 1.51; CI: 1.27–1.79) after adjustment for age group, sex, and
APOE diplotype (Fig. 4).
Figure 4. ORs and CIs for smoking status by (A) AMD phenotype
and by (B) study for late AMD only. Late AMD is composed of all GA,
NV, and GANV samples combined. Smoking status was categorized as
ever smoker versus never smoker. ORs were estimated and adjusted for
age group and gender within each study, for smoking status and APOE
diplotype (late AMD OR = 1.50; CI: 1.36–1.65: P = 7.92 × 10−17). Smoking
status was not significantly associated with increased risk of eAMD
(OR = 0.94; CI: 0.86–1.03; P = 0.16). Tests for heterogeneity in smoking
effect between each late AMD subphenotype were not significant, but a
difference in the effect of smoking was detected between all late AMD
and eAMD. Significant heterogeneity in smoking effect between studies
was detected for late AMD, NV, but not for GA.
The test for differences in the effect of smoking between each late
AMD subphenotype was not significant (χ2 = 3.4, df = 2, P = 0.18),
but a difference in the effect of smoking was detected between late
AMD and eAMD (χ2 = 66.5, df = 1, P < 0.00001; Fig. 4). Significant
heterogeneity in the effect of smoking was also detected between
studies (Fig. 4; eAMD: χ2 = 34.0, df = 14, P = 0.002; NV: χ2 = 48.9,
df = 14, P < 0.001; Late AMD: χ2 = 52.4, df = 14, P < 0.001). Mod-
erate but nonsignificant heterogeneity was detected for the effect of
smoking in GA (χ2 = 21.9, df = 14, P = 0.08) but none in GANV
(χ2 = 11.7, df = 14, P = 0.63).
Test for differences between ever smokers and never smokers
in late AMD risk associated with APOE were obtained by fitting
interaction terms within the logistic regression model. These indi-
cated no significant effect modification by smoking status for either
ε2 (χ2 = 0.08, df = 1, P = 0.78) or ε4 (χ2 = 1.91, df = 1, P = 0.17).
Analysis of APOE diplotype and late AMD in never smokers and
ever smokers separately is presented in Supp. Figure S2.
Extended APOE Haplotype
Genotype data to estimate extended haplotype frequencies
(rs405509, rs429358, and rs7412), with adjustment for age, sex,
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Table 3. Extended Haplotypes were Inferred from Genotype Data at rs405509 (G/T), rs429358 (T/C), and rs7412 (C/T)
Frequency Confidence
Haplotype Case Control Comparisona OR Interval P value
G-ε2 0.069 0.076 G-ε2 vs. T-ε2 1.58 0.85–2.95 0.15
T-ε2 0.021 0.005 1.00
G-ε3 0.441 0.426 G-ε3 vs. T-ε3 0.99 0.88–1.11 0.85
T-ε3 0.371 0.343 1.00
G-ε4 0.027 0.034 G-ε4 vs. T-ε4 1.07 0.71–1.62 0.75
T-ε4 0.071 0.116 1.00
G-ε3/G-ε3 0.184 0.186 1.00
G-ε3/T-ε3 0.343 0.283 G-ε3/T-ε3 vs. G-ε3/G-ε3 1.21 0.98–1.48 0.08
T-ε3/T-ε3 0.135 0.118 T-ε3/T-ε3 vs. G-ε3/G-ε3 0.95 0.74–1.22 0.68
G-ε3/T-ε4 0.083 0.122 G-ε3/T-ε4 vs. G-ε3/G-ε3 0.80 0.60–1.07 0.13
G-ε3/G-ε2 0.063 0.066 G-ε3/G-ε2 vs. G-ε3/G-ε3 1.10 0.79–1.53 0.58
G-ε3/G-ε4 0.020 0.029 G-ε3/G-ε4 vs. G-ε3/G-ε3 0.61 0.38–0.99 0.04
T-ε3/T-ε4 0.053 0.083 T-ε3/T-ε4 vs. G-ε3/G-ε3 0.77 0.55–1.07 0.12
T-ε3/G-ε2 0.069 0.058 T-ε3/G-ε2 vs. G-ε3/G-ε3 1.10 0.79–1.54 0.56
T-ε4/G-ε2 0.018 0.019 T-ε4/G-ε2 vs. G-ε3/G-ε3 1.32 0.73–2.40 0.36
T-ε2/T-ε3 0.012 0.005 T-ε2/T-ε3 vs. G-ε3/G-ε3 1.03 0.51–2.06 0.94
T-ε4/T-ε4 0.003 0.013 T-ε4/T-ε4 vs. G-ε3/G-ε3 0.27 0.08–0.85 0.03
UNPHASED [Dudbridge, 2008] was used to estimate extended haplotype frequencies for late AMD (n = 1,739) and controls (n = 4,725), and to obtain odds ratios (OR) with
95% confidence intervals (CIs) adjusted for age group, center, and smoking status.
Diplotypes with frequency ≤1% in both cases and controls are omitted.
aAdjusted for study, age, gender, and smoking status.
and smoking were available for 1,739 late AMD cases and
4,725 controls. Haplotype frequency estimates using UNPHASED
[Dudbridge, 2008] are presented in Table 3 and linkage disequilib-
rium values in Supp. Figure S3. Comparison of ORs between the
different haplotypes based on the genotype at rs405509 (i.e., G-ε2
vs. T-ε2, G-ε3 vs. T-ε3, G-ε4 vs. T-ε4) showed no significant differ-
ence in effect between G-ε2 and T-ε2 (OR = 1.58; CI: 0.85–2.95; P =
0.15), between G-ε3 and T-ε3 (OR = 0.99; CI: 0.88–1.11; P = 0.85),
or between G-ε4 and T-ε4 (OR = 1.07; CI: 0.71–1.62; P = 0.75) fol-
lowing adjustment for age, sex, and smoking status. Comparison of
extended haplotypes against a reference category G-ε3/G-ε3 did not
identify significant variation in risk beyond G-ε3/G-ε4 (OR = 0.61;
CI: 0.38–0.99; P = 0.04) and T-ε4/T-ε4 (OR = 0.27; CI: 0.08–0.85;
P = 0.03).
Discussion
The results generated for ε4 from this pooled data analysis (OR =
0.72 per haplotype; CI: 0.65–0.79; P = 4.41 × 10–11) provide sup-
port for previous studies that identified a protective role with
late AMD [Bojanowski et al., 2006; Klaver et al., 1998; Souied
et al., 1998]. Previous studies of APOE were dominated by smaller
reports involving multiple comparisons that tend to be more liable
to publication biases. By conducting a pooled analysis in a large
dataset of both published and previously unreported studies, we
attempted to clarify the relationship between AMD risk and APOE.
Variation in geographic distribution of APOE haplotype frequen-
cies as measured in this large study also highlights the limitations
of small studies whose power to detect associations diminishes with
decreased haplotype frequency; for example, the frequency of the ε4
haplotype in the control samples from the Edinburgh study (9.5%)
was less than half that observed in the Melbourne study (20.8%),
and a study in Edinburgh would thus have lower power than a study
in Melbourne for any given sample size.
While the significantly increased risk associated with ε2 for AMD
has been reported previously [Fritsche et al., 2009], most studies
have found nonsignificant increases in risk. This study has demon-
strated a significant increased risk associatedwith ε2ε2 for late AMD
only (OR = 1.83; CI: 1.04–3.23; P = 0.04), with a corresponding low
population attributable risk. The wide CIs and imprecise estimates
associated with the rare ε2ε2 diplotype meant that, although our
results weremost consistentwith a recessive geneticmodel, we could
not entirely exclude an additive genetic model. Little heterogeneity
was detected between studies for the genetic effect exerted by ei-
ther ε2 or ε4 and, indeed, the genetic effects were not significantly
different across all subphenotypes of AMD.
Previous reportshave suggested thatAPOE effectsmaybe stronger
in women [Baird et al., 2004; Schmidt et al., 2002]. Our analyses did
not find evidence of interaction between APOE haplotype risk and
sex. Adjustment for both age and sex within studies was made using
a logistic regression model, to adjust for possible confounding, but
the differing designs of the studies included in this analysis were
such that we could not use the data to assess the effect of age and sex
on AMD risk. This would be best addressed in a population-based
longitudinal study. An earlier meta-analysis examining the effect of
APOE haplotype on coronary risk found no effect modification by
sex inmore than100,000participants [Bennet et al., 2007]. Similarly,
we did not find evidence to support APOE effect modification by
sex in AMD.
Smoking status (ever smoker vs. never smoker) showed an in-
creased risk associated with late AMD (OR = 1.50; CI: 1.36–1.65) af-
ter adjustment for age group, sex, and APOE diplotype, and showed
a nonsignificant difference in effect size between late AMD subphe-
notypes. Our finding of no significant association between smoking
status and eAMDsuggests that smoking exacerbates early symptoms
leading to the progression from eAMD to late AMD, supporting
previous epidemiology-based findings [Clemons et al., 2005; Klein
et al., 2008; Smith et al. 1996; Vingerling et al., 1996; Xu et al.,
2006]. Cigarette smoke may influence macular pigment concentra-
tions [Hammond et al., 1996; Stryker et al., 1988], increase oxidative
stress [Beatty et al., 2000], and impair choroidal microcirculation
[Suner et al., 2004], all processes hypothesized to be involved in the
pathogenesis of AMD. Significant heterogeneity in smoking effect
was detected across studies for late AMD, whichmay be attributable
in part to variation in smoking criteria definitions. Standardization
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of definitions could not be imposed retrospectively beyond the level
of ever smoker versus never smoker. As such, this study is limited
in its ability to estimate the effect of smoking on disease outcome.
Previous reports of effectmodification ofAPOEhaplotype by smok-
ing status were not supported in this study suggesting that APOE
haplotype and smoking status are independent risk factors.
Previously, rs405509 has been implicated in attenuating APOE
promoter activity and subsequent expression [Artiga et al., 1998;
Campillos et al., 2003; Ramos et al., 2005] with possible conse-
quences in attenuating AMD risk [Fritsche et al., 2009]. Results
reported in this analysis, however, do not support an influence of
rs405509, with OR comparisons showing no significant difference
in effect between G-ε2 and T-ε2, G-ε3 and T-ε3, or G-ε4 and T-ε4
following adjustment for age group, sex, and smoking status. How-
ever, several slight differences between this study and that of Fritsche
and colleagues are worthy of consideration. First, Fritsche and col-
leagues comparedhaplotype frequencies between all AMDcases and
controls while this study compared frequencies between late AMD
only and controls. Second, the original study compared the fre-
quency of each haplotype combination against all others combined
while this study compared the frequency of each haplotype against
a single reference haplotype (G-ε3/G-ε3). Third, while rs405509
should sufficiently define the extended APOE haplotype reported
previously, additional SNPs were genotyped by Fritsche and col-
leagues that were not replicated in this study.
The retina hosts the body’s second highest level of APOE pro-
duction after the liver and is likely to play an important role in the
maintenance of normal retinal function [Anderson et al., 2001].
Several possible mechanisms of APOE effect on AMD have been
proposed such as variability in isoform dimerization potential as-
sociated with lipid cholesterol transport or variation in receptor
binding affinity [Klaver et al., 1998]. In addition, the positively
charged ε4 haplotype has been proposed to improve permeability
of Bruch’s membrane, for lipid transport and reducing debris ac-
cumulation associated with drusen formation [Crabb et al., 2002;
Souied et al., 1998]. In older eyes, evidence supporting reduced
lipoprotein transportation across Bruch’s membrane was reported
as a consequence of ageing, leading to drusen deposition and RPE
insult [Curcio et al., 2009]. More recently evidence to support ε4 as
a potential lipoprotein transporter of the macular pigments lutein
and zeaxanthin, has been suggested [Loane et al., 2010] and re-
duced dietary intake of these carotenoids has been associated with
increased risk of AMD [Seddon et al., 1994]. As such, variation in
genes that modulate retinal cholesterol levels may influence AMD
risk [Connor et al., 2007].
The strengths and limitations of the current study should be con-
sidered.Our analysis is almost five times larger thanpublishedmeta-
analyses [Bojanowski et al., 2006; Swaroop et al., 2007; Thakkinstian
et al., 2006] and, although we cannot completely exclude publica-
tion bias in our estimates, this should be limited by our inclusion of
both published and unpublished studies. Access to individual level
data enabled appropriate adjustment to limit potential confounding
by sex, age, and smoking, and assessment of potential interaction
between covariates. In addition, phenotypic subclassification facili-
tated stratification by disease subphenotype identifying smoking as
a major contributing factor to late AMD but not as a risk factor for
the early formof the disease. However, variation in recruitment pro-
cedures between studies and indeed study type, that is, case control
versus population, limited the ability tomeasure the full influence of
age, sex, and smoking on disease risk. Nevertheless, comparison of
effect sizes between population and case control studies, showed no
significant differences in the ORs for ε2ε2, ε4, and smoking status
between the two different study designs.
Recent GWAS identified novel variants in the LIPC and CETP
genes associated with AMD and cholesterol level modulation, sug-
gesting some alleles may influence cholesterol levels in the macula
and in the blood in opposite directions [Chen et al., 2010; Neale
et al., 2010]. Improved understanding of APOE effect on AMD dis-
ease etiology will improve accuracy of AMD risk predictionmodels,
eventually offering some therapeutic benefit. While the complexity
surrounding APOE and cholesterol modulation within the retina
remains, potential benefit derived from statin therapy for the treat-
mentof cardiovasculardisease (CVD)warrants further investigation
in AMD, given the overlap in risk factors for both conditions [Snow
and Seddon, 1999]. While ε4 significantly increases risk associated
with CVD, atherosclerosis, Alzheimer’s disease (AD), and other de-
mentias [Ang et al., 2008], it clearly plays a protective role with
respect to AMD. The mechanisms by which APOE and cholesterol
levels modulate AMD risk, especially with respect to the opposing
effects reported for other complex diseases such as AD and CVD,
are worthy of further investigation.
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